Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Pemetrexed

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44338   clinical trials with a EudraCT protocol, of which   7368   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    321 result(s) found for: Pemetrexed. Displaying page 1 of 17.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2005-004030-40 Sponsor Protocol Number: TOGA 0502 Start Date*: 2006-02-06
    Sponsor Name:Thoracale Oncologie Groep Antwerpen
    Full Title: A RANDOMIZED MULTICENTER PHASE II STUY OF INDUCTION THERAPY WITH PEMETREXED AND CISPLATIN FOLLOWED BY CHEMORADIATION WITH PEMETREXED VERSUS CHEMORADIATION WITH PEMETREXED FOLLOWED BY CONSOLIDATION ...
    Medical condition: Non-Small Cell Lung Cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2022-001975-15 Sponsor Protocol Number: NL77514.078.21 Start Date*: 2022-07-26
    Sponsor Name:
    Full Title: The effect of extra hydration on kidney function during carboplatinpemetrexed-pembrolizumab in patients with advanced non-small cell lung cancer.
    Medical condition: Patient with advanced non-small cell lung cancer receiving treatment with carboplatin-pemetrexed-pembrolizumab.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2019-003372-39 Sponsor Protocol Number: INCMGA0012-304 Start Date*: 2020-06-21
    Sponsor Name:Incyte Corporation
    Full Title: A Randomized, Double Blind, Phase 3 Study of Platinum-Based Chemotherapy With or Without INCMGA00012 in First-Line Metastatic Squamous and Nonsquamous Non–Small Cell Lung Cancer (POD1UM-304)
    Medical condition: Male and female participants at least 18 years of age (or as per adult age applicable per local country requirements) who have metastatic nonsquamous or squamous NSCLC.
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004864 10080083 Advanced lung cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Prematurely Ended) CZ (Trial now transitioned) BG (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2015-003605-42 Sponsor Protocol Number: GO29438 Start Date*: 2016-04-14
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A PHASE III, OPEN-LABEL, RANDOMIZED STUDY OF ATEZOLIZUMAB (MPDL3280A, ANTI?PD-L1 ANTIBODY) IN COMBINATION WITH CARBOPLATIN OR CISPLATIN+PEMETREXED COMPARED WITH CARBOPLATIN OR CISPLATIN+PEMETREXED ...
    Medical condition: Metastatic non-squamous non-small cell lung cancer
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004864 10029514 Non-small cell lung cancer NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) RO (Completed) BE (Completed) LT (Completed) SK (Completed) PT (Completed) HU (Completed) AT (Completed) LV (Completed) FR (Completed) NL (Completed) HR (Prematurely Ended) IT (Completed)
    Trial results: View results
    EudraCT Number: 2008-002035-33 Sponsor Protocol Number: 65 plus Start Date*: 2009-04-20
    Sponsor Name:Martha-Maria Krankenhaus Halle-Dölau gGmbH
    Full Title: Open-label study of Bevacizumab (AVASTIN®) in combination with Pemetrexed or Pemetrexed and Carboplatin as first-line treatment of patients with advanced or recurrent non-squamous non-small cell lu...
    Medical condition: Patients with advanced metastatic or recurrent non- small cell lung cancer (NSCLC).
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-004009-24 Sponsor Protocol Number: GOIRC 02/2006 Start Date*: 2006-12-12
    Sponsor Name:GRUPPO ONCOLOGICO ITALIANO DI RICERCA
    Full Title: Randomized phase II study of pemetrexed versus pemetrexed and carboplatin as second line chemotherapy in advanced non-small-cell lung cancer (NSCLC).
    Medical condition: Previously treated patients with locally advanced or metastatic non-small cell lung cancer (NSCLC).
    Disease: Version SOC Term Classification Code Term Level
    9.1 10059515 Non-small cell lung cancer metastatic LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-007623-40 Sponsor Protocol Number: D4320C00035 Start Date*: 2008-09-05
    Sponsor Name:AstraZeneca AB
    Full Title: A Phase II, Double-blind, Placebo-Controlled, Randomised Study to Assess the Efficacy and Safety of ZD4054 in Combination with Pemetrexed (Alimta®) vs. Pemetrexed Alone in Patients with Non-small C...
    Medical condition: Locally advanced or metastatic Non small cell lung cancer (NSCLC) without predominantly squamous cell histology
    Disease: Version SOC Term Classification Code Term Level
    9.1 10066490 Progression of non small cell lung cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing) CZ (Completed) BG (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-000095-28 Sponsor Protocol Number: H3E-MC-JMHW Start Date*: 2017-03-02
    Sponsor Name:Eli Lilly and Company
    Full Title: A Phase II Study of Pemetrexed in Children with Recurrent Malignancies
    Medical condition: Recurrent Malignancies (recurrent solid tumors): Target tumor types were osteosarcoma, Ewing sarcoma/peripheral PNET, rhabdomyosarcoma, neuroblastoma (measurable disease), neuroblastoma (metaiodob...
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2018-004791-36 Sponsor Protocol Number: BCD-100-3/DOMAJOR Start Date*: 2019-09-09
    Sponsor Name:JSC BIOCAD
    Full Title: International Multicenter Randomized Double-Blind Placebo-Controlled Clinical Trial Evaluating Efficacy and Safety Of BCD-100 in combination with Pemetrexed+Cisplatin/Carboplatin Compared to Placeb...
    Medical condition: Advanced Non-squamous Non-Small Cell Lung Cancer (NSCLC)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10079440 Non-squamous non-small cell lung cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Completed) HU (Completed) RO (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-000634-33 Sponsor Protocol Number: D967SC00001 Start Date*: 2021-11-02
    Sponsor Name:ASTRAZENECA AB
    Full Title: An Open-label, Randomized, Multicenter, Phase 3 Study to Assess the Efficacy and Safety of Trastuzumab Deruxtecan as First-line Treatment of Unresectable, Locally Advanced, or Metastatic NSCLC Harb...
    Medical condition: Unresectable, locally advanced, or metastatic Non-Small Cell Lung Cancer with HER2 exon 19 or 20 mutations
    Disease: Version SOC Term Classification Code Term Level
    24.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10084787 HER2 mutant non-small cell lung cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Trial now transitioned) NL (Trial now transitioned) ES (Ongoing) FR (Trial now transitioned) BE (Trial now transitioned) DK (Trial now transitioned) PL (Trial now transitioned) DE (Trial now transitioned) AT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2015-005143-13 Sponsor Protocol Number: ONCOS-C719 Start Date*: 2016-05-06
    Sponsor Name:Targovax Oy
    Full Title: A randomised Phase II open-label study with a Phase Ib safety lead-in cohort of ONCOS-102, an immune-priming GM-CSF coding oncolytic adenovirus, and pemetrexed/cisplatin in patients with unresectab...
    Medical condition: Patients with unresectable malignant pleural mesothelioma
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004864 10049280 Solid tumour LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2009-011327-31 Sponsor Protocol Number: GECP0901PHALCIS Start Date*: 2009-08-18
    Sponsor Name:Grupo Español de Cáncer de Pulmón
    Full Title: Estudio de pemetrexed y cisplatino como tratamiento de primera línea en pacientes con cáncer de pulmón no escamoso, avanzado: estudio farmacogenómico en fase IIA (Study of pemetrexed disodium plus...
    Medical condition: Cáncer de Pulmón no microcítico (Non-small lung cancer, non squamous)
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2012-001598-10 Sponsor Protocol Number: UCL/12/0158 Start Date*: 2012-12-21
    Sponsor Name:University College London
    Full Title: A phase I/II study of first line Ganetespib with pemetrexed/cisplatin, in patients with malignant pleural mesothelioma
    Medical condition: Malignant pleural mesothelioma
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10035603 Pleural mesothelioma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2018-004720-11 Sponsor Protocol Number: MK-7339-006 Start Date*: 2019-06-18
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: A Phase 3 Study of Pembrolizumab in Combination with Pemetrexed/Platinum (Carboplatin or Cisplatin) Followed by Pembrolizumab and Maintenance Olaparib vs Maintenance Pemetrexed in the First-Line Tr...
    Medical condition: Stage IV lung cancer condition
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029522 Non-small cell lung cancer stage IV PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10059515 Non-small cell lung cancer metastatic PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10079440 Non-squamous non-small cell lung cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) AT (Trial now transitioned) DE (Trial now transitioned) FR (Trial now transitioned) PL (Trial now transitioned) GB (GB - no longer in EU/EEA) RO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2011-001111-31 Sponsor Protocol Number: 20101128 Start Date*: 2013-09-09
    Sponsor Name:Amgen Inc
    Full Title: A Phase 1b/2 Trial of AMG 386 in Combination With Pemetrexed and Carboplatin as First Line Treatment of Metastatic Non-Squamous Non-Small Cell Lung Cancer
    Medical condition: Metastatic Non-Squamous Non-Small Cell Lung Cancer
    Disease: Version SOC Term Classification Code Term Level
    16.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10059515 Non-small cell lung cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) ES (Completed) GR (Completed)
    Trial results: View results
    EudraCT Number: 2015-003694-15 Sponsor Protocol Number: MK-3475-189 Start Date*: 2016-03-04
    Sponsor Name:Merck Sharp & Dohme LLC
    Full Title: A Randomized, Double-Blind, Phase III Study of Platinum+Pemetrexed Chemotherapy with or without Pembrolizumab (MK-3475) in First Line Metastatic Non-squamous Non-small Cell Lung Cancer Subjects (KE...
    Medical condition: non-squamous non-small cell lung cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10079440 Non-squamous non-small cell lung cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Completed) DE (Completed) GB (GB - no longer in EU/EEA) AT (Completed) BE (Completed) ES (Completed) NL (Completed) FI (Completed) DK (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2008-007008-27 Sponsor Protocol Number: MO22089 Start Date*: 2009-07-03
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: Open label study of bevacizumab maintenance therapy (AVASTIN) with or without pemetrexed after a first line treatment chemotherapy with bevacizumab-cisplatin-pemetrexed in patients with advanced, m...
    Medical condition: Locally advanced (stage IIIb with supraclavicular lymph node metastases or malignant pleural or pericardial effusion), metastatic or recurrent non squamous non-small cell lung cancer (NSCLC)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10029521 Non-small cell lung cancer stage IIIB LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) SE (Completed) ES (Completed) IT (Completed) NL (Completed) DE (Completed) GR (Completed)
    Trial results: View results
    EudraCT Number: 2013-004698-29 Sponsor Protocol Number: TH-CR-415 Start Date*: 2014-05-12
    Sponsor Name:Threshold Pharmaceuticals, Inc.
    Full Title: A Randomized Phase 2, Double-blind, Placebo-controlled, Multi-center Study Comparing Pemetrexed in Combination with TH-302 vs. Pemetrexed in Combination with Placebo as Second-line Chemotherapy for...
    Medical condition: Advanced Non-Squamous, Non-Small Cell Lung Cancer
    Disease: Version SOC Term Classification Code Term Level
    18.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029522 Non-small cell lung cancer stage IV PT
    18.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029521 Non-small cell lung cancer stage IIIB PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Prematurely Ended) IT (Completed) DE (Prematurely Ended) CZ (Completed) GR (Prematurely Ended) ES (Temporarily Halted) RO (Completed)
    Trial results: View results
    EudraCT Number: 2004-002782-20 Sponsor Protocol Number: H3E-MC-JMHH Start Date*: 2005-04-15
    Sponsor Name:Eli Lilly and Company Limited
    Full Title: A Phase 1 and 2 Clinical Trial of ALIMTA (Pemetrexed) in Combination with Carboplatin in Patients with Recurrent Ovarian or Primary Peritoneal Cancer
    Medical condition: platinum sensitive recurrent ovarian or primary peritoneal cancer
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DE (Completed) SE (Completed)
    Trial results: View results
    EudraCT Number: 2006-003695-35 Sponsor Protocol Number: D4200C00036 Start Date*: 2007-01-24
    Sponsor Name:AstraZeneca AB
    Full Title: A Phase III, Randomized, Double-blinded, Parallel Group, Multi-centre Study to Assess the Efficacy and Safety of ZD6474 (ZACTIMA™) in Combination with Pemetrexed (Alimta®) versus Pemetrexed alone i...
    Medical condition: Locally-advanced or Metastatic (stage IIIB or IV) Non-Small Cell Lung Cancer (NSCLC).
    Disease: Version SOC Term Classification Code Term Level
    8.1 10029514 Non-small cell lung cancer NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) DE (Completed) GR (Ongoing) PT (Completed) IT (Completed) BE (Completed) GB (Completed) ES (Completed) FR (Ongoing)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 24 17:33:19 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA